Health TrialsbyHealthPanel

Effects of X Box Kinect 360 in Alzheimer's Disease

ConditionAlzheimer s Disease
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-85
SponsorZiauddin University

About this trial

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia that accounting for 60% to 80% of all cases (Better, et al., 2023). According to world health organization (WHO), more than 55 million people globally live with dementia, and this number is expected to rise to 78 million by 2023 and 139 million by 2050 (WHO, 2021).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Alzheimer's disease of age between 50-85 years.

Diagnosed AD stage Mild to Moderate.

Disqualifiers

Undiagnosed AD patients.

Mental or neurological conditions like schizophrenia, Parkinson's, or stroke.

Trial design

Design model

Parallel

Treatments tested in this trial

  • 3D Kinect based game

    Other intervention

    Experimental group will receive X boc kinect 360 bomb such as match makers, traffic control, mouse mayhem, strike a pose, pizza catch, flag frenzy, follow the arrow for 30 minutes for five days a week, for six weeks.

  • Conventional therapy group

    Other intervention

    The intervention will run for 30 minutes (excluding rest period), five days a week, for six weeks (Deng, et al., 2025). The patients will take 1-2 minutes rest after 5 minutes of activity. Rest periods of 1-2 minutes after every 5 minutes of activity.

Treatment groups

38 Participants
are divided into 2 treatment groups
Group A: Arms 1Experimental treatment 1 intervention
Group B: Arm 2Placebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Cognition

Cognitive function will be assessed through among mild to moderate AD patients where low values indicate decrease in cognitive ability.

Time frame
Baseline
2

Cognition

Cognitive function will be assessed through Mini- Cog among Mild to Moderate AD patients where low values indicate decrease cognitive function

Time frame
After 6 week of Intervention
3

Motor Function

Motor function will be assessed using the Timed Up and Go (TUG) Test among patients with mild to moderate Alzheimer's disease (AD), where higher scores (longer completion times) indicate poorer functional mobility

Time frame
Baseline
4

Motor Function

Motor function will be assessed using the Timed Up and Go (TUG) Test among patients with mild to moderate Alzheimer's disease (AD), where higher scores (longer completion times) indicate functional mobility

Time frame
After 6 week of intervention

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Ziauddin University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: